Your web browser doesn’t have the Flash Player v.9 plugin installed, so this Website can’t be properly viewed.
For full experience, please download the latest Flash plugin at Adobe.com.
Download Adobe Flash Player now.

GARDASIL®

Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine


GARDASIL® AND YOUR SON OR DAUGHTER

GARDASIL® is a vaccine that helps protect against 4 types of HPV: 2 types that cause 70% of cervical cancers in women, and 2 more types that cause 90% of genital wartsGenital wartsGenital warts are usually flesh-coloured growths that are caused by certain types of HPV. Learn more about genital warts.
Get More Information
See Full Glossary
View Photos
in men and women.

GARDASIL® has also been shown to help protect against vulvar and vaginal cancers, as well as abnormal and precancerous cervical cells (as found in abnormal Pap tests) in women.

GARDASIL® also helps protect against anal cancer and abnormal and precancerous anal lesions in females and males ages 9 to 26.

GARDASIL® is indicated for girls and women ages 9 to 45, and for boys and men ages 9 to 26.

You can help protect your son/daughter from HPV by getting him/her vaccinated with GARDASIL® today

Like other vaccines your son/daughter may have received, GARDASIL® works to help prevent illness. GARDASIL® works best when given before there is any contact with HPV types 6, 11, 16 and 18. That’s why boys and girls as young as 9 can get vaccinated.

  • For girls 9 to 13 years of age, as this is generally before the onset of sexual intercourse
  • For girls and women 14 to 26 years of age even if they are already sexually active, have had previous Pap abnormalities, cervical cancer, genital warts or HPV infection
  • For males 9 to 26 years of age for the prevention of anal cancer and genital warts

When you’re ready, you’ll be able to share the facts with him/her. But by getting your daughter vaccinated with GARDASIL® now, you’ll be helping to protect her against 4 types of HPV and the diseases it can cause such as cervical cancer, genital warts, vulvar and vaginal cancers and abnormal and precancerous cervical, vaginal and vulvar cells before she’s old enough to worry about them. By getting your son vaccinated with GARDASIL® now, you’ll be helping to protect him against 4 types of HPV and genital warts caused by types 6 and 11 before he’s old enough to worry about them.


THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION STATES THAT
GARDASIL® MAY BE ADMINISTERED TO FEMALES OVER 26 YEARS OLD,
GRADE A RECOMMENDATION By clicking on this link, you will be leaving this site This link will take you to a site outside of Merck Canada Inc.

Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
Proceed


See what other Canadian medical groups support HPV vaccination

More than

  • 3.3 million doses of GARDASIL® have been distributed in Canada†
  • 79 million doses of GARDASIL® have been distributed worldwide†

†Clinical significance is unknown. The number of doses administered is unknown.

IMPORTANT INFORMATION ABOUT GARDASIL®

In girls and women ages 9 to 45, GARDASIL® helps prevent infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: cervical, vaginal, and vulvar cancers caused by HPV types 16 and 18; abnormal and precancerous vaginal and vulvar lesions, abnormal and precancerous cervical lesions as found in Pap tests, caused by types 6, 11, 16 and 18; and genital warts caused by types 6 and 11.

In girls and women ages 9 to 26, GARDASIL® also helps protect against anal cancer caused by HPV types 16 and 18, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.

In boys and men ages 9 to 26, GARDASIL® helps protect against infection caused by HPV types 6, 11, 16 and 18 and the following diseases associated with the HPV types included in the vaccine: anal cancer caused by HPV types 16 and 18, genital warts caused by types 6 and 11, and abnormal and precancerous anal lesions caused by types 6, 11, 16 and 18.

GARDASIL® helps prevent these diseases, but it does not treat them. And just like all vaccines, GARDASIL® may not fully protect everyone who gets it. GARDASIL® does not protect against all types of HPV. Duration of protection continues to be studied. GARDASIL® does not protect against other sexually transmitted infections.

Even if vaccinated with GARDASIL®, it is still important for women to continue having regular Pap tests. Recipients of GARDASIL® should not discontinue anal cancer screening if it has been recommended by a healthcare provider. Vaccination with GARDASIL® is not recommended during pregnancy.

Like all vaccines, GARDASIL® may cause some side effects. GARDASIL® has been shown to be generally well tolerated in adults and children as young as age 9. The most commonly reported side effects included pain, swelling, itching, bruising and redness where the shot was given, fever, nausea, dizziness, headache, vomiting and pain in extremity.

Fainting has been reported. Fainting can occur after vaccination, most commonly among adolescents and young adults. Although fainting episodes are uncommon, vaccinees should be observed for 15 minutes after they receive GARDASIL®.

Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives, and rash have been reported.

These were not all the side effects reported. If you notice any unusual or severe symptoms after receiving GARDASIL®, contact your healthcare professional as soon as possible.

Information about GARDASIL® is provided in the Consumer Information. To retrieve this information you will be re-directed to a page within our main Merck Website, which contains the Consumer Information.

Click here to go to the Gardasil® Consumer Information.

To view PDF documents, you must have Adobe Acrobat Reader®

To view PDF documents, you must have Adobe Acrobat Reader® By clicking on this link, you will be leaving this site This link will take you to a site outside of Merck Canada Inc.

Merck does not review or control the content of any non-Merck site. Merck does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Merck site.
Proceed
installed on your computer.







This site is intended only for residents of Canada. This Website is for information purposes only.
® Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Used under license.

© 2010-2012 Merck Canada Inc., a subsidiary of Merck & Co., Inc. All rights reserved.
VACC-1018251-0000-E-CDN-OCT-13